• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 425 filed by Bellevue Life Sciences Acquisition Corp.

    2/13/25 4:14:40 PM ET
    $BLAC
    Blank Checks
    Finance
    Get the next $BLAC alert in real time by email
    425 1 ea0230563-8k425_bellevue.htm CURRENT REPORT

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): February 13, 2025

     

    OSR HOLDINGS, INC

    (Exact Name of Registrant as Specified in Charter)

     

    Delaware   001-41390   84-5052822
    (State or Other Jurisdiction   (Commission File Number)   (IRS Employer
    of Incorporation)       Identification No.)

     

    10900 NE 4th Street, Suite 2300, Bellevue, WA   98004
    (Address of Principal Executive Offices)   (Zip Code)

     

    Registrant’s telephone number, including area code (425) 635-7700

     

    BELLEVUE LIFE SCIENCES ACQUISITION CORP.
    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☒ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Units, each consisting of one share of common stock, one redeemable warrant and one right   BLACU   The Nasdaq Stock Market LLC
    Common stock, par value $0.0001 per share   BLAC   The Nasdaq Stock Market LLC
    Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share   BLACW   The Nasdaq Stock Market LLC
    Right to receive one-tenth (1/10) of one share of common stock   BLACR   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.03. Amendments to Certificate of Incorporation or Bylaws; Change in Fiscal Year.

    On February 13, 2025, Bellevue Life Sciences Acquisition Corp. (“BLAC”) filed an Amended and Restated Certificate of Incorporation with the Secretary of the State of Delaware. The terms of the Amended and Restated Certificate of Incorporation are described in the proxy statement (the “Proxy Statement”) for the special meeting of stockholders held by BLAC on February 13, 2025 (the “Special Meeting”). A copy of BLAC’s Amended and Restated Certificate of Incorporation is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

     

    On February 13, 2025, BLAC held the Special Meeting to vote on the proposals described in the Proxy Statement.

     

    There were 2,319,752 shares of BLAC common stock, par value $0.0001 per share (“BLAC Common Stock”), outstanding at the close of business on January 27, 2025, the record date for the Special Meeting. At the Special Meeting, the holders of 2,179,383 shares of BLAC Common Stock, or 93.95% of the voting power of all outstanding BLAC Common Stock were represented in person or by proxy, which constituted a quorum.

     

    Set forth below are the proposals voted upon at the Special Meeting (each of which is described in the Proxy Statement) and the final voting results.

     

    Proposal No. 1 – The Business Combination Proposal

     

    A proposal to approve the business combination (the “Business Combination”) reflected by the Amended and Restated Business Combination Agreement, dated May 23, 2024, as amended on December 20, 2024 (the “Business Combination Agreement”).

     

    FOR   AGAINST   ABSTAIN
    2,175,065   4,318   --

      

    Proposal No. 2 – The Charter Proposal

     

    A proposal to approve the Amended and Restated Certificate of Incorporation of BLAC (the “Amended Charter”).

     

    FOR   AGAINST   ABSTAIN
    2,175,065   4,318   --

      

    Proposals No. 3A-3F – The Advisory Governance Proposals

     

    Six separate governance proposals (on a non-binding advisory basis in accordance with the requirements of the U.S Securities and Exchange Commission) relating to material differences between the current certificate of incorporation and the Amended Charter, and the current bylaws of BLAC and Amended and Restated Bylaws of BLAC to be in effect upon completion of the Business Combination. Specifically:

     

    3A:Name Change – To change BLAC’s name to “OSR Holdings, Inc.”

     

    FOR   AGAINST   ABSTAIN
    2,175,065   4,318   --

     

    3B:Preferred Stock – To increase the number of shares of preferred stock that can be issued from 1,000,000 shares to 20,000,000 shares.

     

    FOR   AGAINST   ABSTAIN
    2,175,065   4,318   --

      

    3C:Increase Vote Required for Removal of Directors – To provide that directors may be removed by the affirmative vote of the holders of at least 66 2/3% of the voting power instead of for cause and by the affirmative vote of holders of a majority of the voting power.

     

    FOR   AGAINST   ABSTAIN
    2,175,065   4,318   --

     

     

     

     

    3D:Corporate Opportunity – To eliminate the current limitations on the corporate opportunity doctrine.

     

    FOR   AGAINST   ABSTAIN
    2,179,383   --   --

      

    3E:Change in Quorum – To provide that the quorum required for stockholder meetings is the holders of one-third in voting power of the then outstanding shares of capital stock entitled to vote at the meeting instead of the holders of a majority in voting power of the then outstanding shares of capital stock entitled to vote at the meeting.

     

    FOR   AGAINST   ABSTAIN
    2,175,065   4,318   --

      

    3F:Additional Charter Amendments – To approve all other changes including eliminating certain provisions related to special purpose acquisition companies that will no longer be relevant following the closing of the Business Combination.

     

    FOR   AGAINST   ABSTAIN
    2,175,065   4,318   --

      

    Proposal No. 4 – The Incentive Plan Proposal

     

    A proposal to adopt the new omnibus incentive plan in the form attached as Annex H to the Proxy Statement.

     

    FOR   AGAINST   ABSTAIN
    2,175,065   4,318   --

      

    Proposal No. 5 – The Director Election Proposal

     

    A proposal to elect nine (9) individuals as directors of BLAC following the closing of the Business Combination until their respective successors are duly elected and qualified.

     

    1. Kuk Hyoun Hwang

     

    FOR   WITHHOLD
    2,175,065   4,318

      

    2. Jun Chul Whang

     

    FOR   WITHHOLD
    2,175,065   4,318

     

    3. Phil Geon Lee

     

    FOR   WITHHOLD
    2,175,065   4,318

     

    4. Alcide Barberis

     

    FOR   WITHHOLD
    2,175,065   4,318

      

    5. Seng Chin Mah

     

    FOR   WITHHOLD
    2,175,065   4,318

     

     

     

     

    6. Jin Whan Park

     

    FOR   WITHHOLD
    2,175,065   4,318

     

    7. Sang Hyun Kim

     

    FOR   WITHHOLD
    2,175,065   4,318

     

    8. Hyuk Joo Jee

     

    FOR   WITHHOLD
    2,175,065   4,318

     

    9. Joong Myung Cho

     

    FOR   WITHHOLD
    2,175,065   4,318

     

    Proposal No. 6 – The Nasdaq Proposal

     

    A proposal to approve, for purposes of complying with the applicable listing rules of the Nasdaq Stock Market LLC, the issuance of shares of BLAC common stock pursuant to the Business Combination Agreement in connection with the Business Combination.

     

    FOR   AGAINST   ABSTAIN
    2,175,065   4,318   --

     

    Proposal No. 7 – The Adjournment Proposal

     

    As there were sufficient votes to approve the above proposals, the “Adjournment Proposal” described in the Proxy Statement was not presented to shareholders.

     

    Item 8.01 Other Events.

     

    Redemptions

     

    In connection with the votes to approve certain of the above proposals, 57,821 shares of BLAC Common Stock were tendered for redemption.

     

    Press Release

     

    On February 13, 2025, OSR Holdings, Inc. issued a press release announcing the results of the Special Meeting. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Description
    3.1   Amended and Restated Certificate of Incorporation
    99.1   Press Release, dated February 13, 2025
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    No Solicitation or Offer

     

    This communication and this Current Report on Form 8-K shall not constitute an offer to sell or exchange or the solicitation of an offer to buy or exchange any securities pursuant to the Business Combination or otherwise, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: February 13, 2025

     

      OSR HOLDINGS, INC
       
      By: /s/ Kuk Hyoun Hwang
        Name: Kuk Hyoun Hwang
        Title: Chief Executive Officer

     

     

     

     

    Get the next $BLAC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BLAC
    SEC Filings

    View All

    Bellevue Life Sciences Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Change in Shell Company Status, Leadership Update, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Financial Statements and Exhibits

    8-K - OSR Holdings, Inc. (0001840425) (Filer)

    2/21/25 4:10:12 PM ET
    $BLAC
    Blank Checks
    Finance

    SEC Form 25-NSE filed by Bellevue Life Sciences Acquisition Corp.

    25-NSE - OSR Holdings, Inc. (0001840425) (Subject)

    2/18/25 8:16:26 AM ET
    $BLAC
    Blank Checks
    Finance

    SEC Form 425 filed by Bellevue Life Sciences Acquisition Corp.

    425 - Bellevue Life Sciences Acquisition Corp. (0001840425) (Subject)

    2/13/25 4:14:40 PM ET
    $BLAC
    Blank Checks
    Finance

    $BLAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OSR Holdings Announces Strategic Roadmap for Tokenization Under Reg D Framework in Partnership with BCM Europe AG

    BELLEVUE, Wash. and ZUG, Switzerland, July 8, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare company advancing biomedical and wellness innovation, today announced the official roadmap for a targeted $50 million security token offering (STO) planned for launch in the second half of 2025 under Regulation D of the U.S. Securities Act. The token, with the working title OSRT, will be a securitized digital asset representing OSR Holdings' equity exposure and is designed to align with the company's blockchain-based capital strategy. As part of this roadmap

    7/8/25 10:03:00 AM ET
    $BLAC
    $OSRH
    Blank Checks
    Finance
    Medical/Dental Instruments
    Health Care

    OSR Holdings, BCM Europe, and Taekwondo Cooperative Announce Strategic MOU to Launch Blockchain-Based OSRH Token

    SEOUL, South Korea and ZUG, Switzerland, May 22, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH), a public company dedicated to advancing innovation in healthcare and wellness, announced today that it has entered into a Memorandum of Understanding (MOU) with BCM Europe AG, its major shareholder, and Taekwondo Cooperative (TKD Coop), a global Taekwondo community organization, to explore the joint development of a security token, provisionally named the "OSRH Token". The initiative aims to enhance access to crypto-based liquidity and provide a basis for OSRH to launch crypto treasury strategies.

    5/22/25 7:36:00 AM ET
    $BLAC
    $OSRH
    Blank Checks
    Finance
    Medical/Dental Instruments
    Health Care

    OSR Holdings, Inc. and OSR Holdings Co., Ltd. Announce Completion of Business Combination

    OSR Holdings, Inc. to Begin Trading on the Nasdaq Stock Market LLC on Tuesday, February 18, 2025Under the symbol "OSRH" SEOUL, South Korea, Feb. 14, 2025 /PRNewswire/ -- OSR Holdings, Inc. (formerly Bellevue Life Sciences Acquisition Corp. (the "Company")) and OSR Holdings Co., Ltd. ("OSR") announced today the completion of their business combination (the "Business Combination"). The Company now operates as "OSR Holdings, Inc." following the successful completion of the Business Combination.  Beginning on Tuesday, February 18, 2025, the common stock and warrants of the Company

    2/14/25 6:10:00 PM ET
    $BLAC
    Blank Checks
    Finance

    $BLAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Kim Sang Harry

    3 - OSR Holdings, Inc. (0001840425) (Issuer)

    2/21/25 4:15:09 PM ET
    $BLAC
    Blank Checks
    Finance

    SEC Form 3 filed by new insider Cho Joong Myung

    3 - OSR Holdings, Inc. (0001840425) (Issuer)

    2/21/25 4:15:12 PM ET
    $BLAC
    Blank Checks
    Finance

    SEC Form 3 filed by new insider Barberis Alcide

    3 - OSR Holdings, Inc. (0001840425) (Issuer)

    2/21/25 4:15:10 PM ET
    $BLAC
    Blank Checks
    Finance

    $BLAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bellevue Life Sciences Acquisition Corp.

    SC 13G - Bellevue Life Sciences Acquisition Corp. (0001840425) (Subject)

    11/14/24 4:47:55 PM ET
    $BLAC
    Blank Checks
    Finance

    Amendment: SEC Form SC 13G/A filed by Bellevue Life Sciences Acquisition Corp.

    SC 13G/A - Bellevue Life Sciences Acquisition Corp. (0001840425) (Subject)

    8/14/24 8:00:58 AM ET
    $BLAC
    Blank Checks
    Finance

    SEC Form SC 13G filed by Bellevue Life Sciences Acquisition Corp.

    SC 13G - Bellevue Life Sciences Acquisition Corp. (0001840425) (Subject)

    2/8/24 4:20:10 PM ET
    $BLAC
    Blank Checks
    Finance